Elan reports "solid" start to 2012
UPDATE: Elan has reported a 17 per cent rise in revenues for the first quarter of the year and says opportunities in neurology are significant.
Elan has reported a 17 per cent rise in revenues for the first quarter of the year.
Revenues at the firm that focuses on neurological disorders totalled $288.4 million in the three months, Elan said.
Revenue from its multiple sclerosis drug Tysabri totalled $288.2 million, which was just ahead of expectations according to Bloomberg News.
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month
*New subscribers only
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Quarterly
€55
€42
90 Day Pass
2 Yearly
€315
€248
Unlimited Access for 2 Years
Team Pass
Get a Business Account for you and your team
Related Stories
The year in review
The best writing and and the biggest stories of 2019 from the Business Post
Newsround: What Thursday’s papers say
Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals
More cycle routes, expansion of Luas to Bray and new bus network proposed
Greater Dublin Area draft Transport Strategy published
